dismutase (SOD1) in amyotrophic lateral sclerosis [12] . This interaction is required for the ubiquitin ligase function of Dorfin. While gp78 and Rma1 have been described to be involved in degradation of phenylalanine mutant of cystic fibrosis transmembrane regulator (⌬F508-CFTR) by our group and more recently by other groups [16] [17] [18] . The gp78-VCP complex is also known to be involved in degradation of other misfolded proteins like CD3delta, Z variant of alpha-1-trypsin and HMG CoA reductase, a rate-limiting enzyme in cholesterol synthesis [14, 19, 20] . VCP-gp78 interaction is known to enhance both ubiquitination and VCP-polyubiquitin binding during ERAD [14] .
In addition to its pivotal role in ubiquitin-dependent protein degradation [7] , VCP binds to expanded polyglutamine protein aggregates [9] and has been shown to have this polyglutamine protein binding capacity in Huntington's disease and spinocerebellar ataxia type III (SCA III) [9, 10] . Recently, Schroder et al. [11] presented a report of a patient with a VCP mutation leading to an inclusion body myopathy with frontotemporal dementia (IBMFD), a protein deposition disorder. While Klein et al . [8] [21, 22] . Taken together, (1) 
demonstrated that VCP is phosphorylated by the anti-apoptotic affinity-regulating kinase (Akt) that regulates ERAD pathway. More recently, small VCP interacting protein (SVIP) has been identified as an endogenous inhibitor of VCP ERAD function

VCP has a key function in protein ubiquitilation in the ERAD pathway, thereby, being regulated through phosphorylation by Akt, endogenous regulator SVIP or through interaction with Dorfin/gp78/Rma1. These multiple interactions in protein degradation pathways points to an important role of VCP in protein degradation disorders such as amyotrophic lateral sclerosis and inclusion body myopathies. (2) VCP mutations can be responsible for a nuclear inclusion body type of frontotemporal dementia. (3)
We and others recently showed that VCP specifically binds to mutant-CFTR protein as compared to wt-CFTR followed by its proteasome-mediated degradation [15, 23] .
There is emerging evidence on association of VCP expression with chronic inflammatory pathology in diseases such as cystic fibrosis, alpha-1-antitrypsin deficiency and idiopathic pulmonary fibrosis (IPF) [24, 25] [26] . We recently proposed that VCP is a novel target for not only rescuing misfolded protein from proteasomal degradation but also IB, endogenous inhibitor of NFB-mediated chronic inflammation associated with chronic pathophysiology of these diseases [15] . Several recent reviews discuss the role of VCP in ERAD, apoptotic signalling and neurodegenerative disorders [1, 27, 28] . We discuss and provide here the perspective on cellular functions of VCP, its association with the disease and the proposed therapeutic potential.
Role of VCP in inflammatory signalling and ER stress
We observed overexpression of VCP protein in CF primary epithelial cells obtained at bronchoscopy from ⌬F508 CF subjects as compared to non-CF controls [15] [29, 30] . Cell lines overexpressing VCP demonstrate resistance to apoptosis, and increased metastatic potential [31] . The anti-apoptotic and prometatstatic effects of VCP occur via activation of the NFB signalling pathway [31] ; this pathway has seminal importance in pancreatic cancer and numerous reports confirm activation of NFB signalling in the majority of cases [32] [33] [34] . We have preliminary data demonstrating that VCP inhibition not only rescues IB (the endogenous inhibitor of NFkB) from proteasomal degradation but also independently suppresses NFB activation [15, 35] 
Role of VCP in ERAD and protein aggregation
In addition to its association with Derlin1 complex on ER membrane [36] , VCP is also found in aggresomes containing ⌬F508-CFTR [37] in association with cytosolic histone deacetylase, HDAC6. These ⌬F508-CFTR containing aggresome bodies are detectable following proteasome inhibition. It was recently reported that finely tuned balance of the associations of HDAC6 and VCP with ⌬F508-CFTR determines its fate [38] . [18] . We confirmed the functional association of VCP with ERAD and aggresome formation using small molecule inhibitor of aggresome formation (tubacin) and proteasome inhibition (Fig. 1 [5, [47] [48] [49] [50] . VCP is also known to interact with proteins involved in membrane trafficking [51] as summarized in Table 2 
This study used the ⌬F508-CFTR mutant that lacked its C-terminal ATPase domain (deletion of 1057-1480 region). Recently, we used the N-terminal truncated form of CFTR (⌬264-CFTR) and ⌬F508-CFTR to demonstrate that small molecule inhibition of HDAC6 induces the proteasome inhibitor-mediated CFTR rescue from ERAD [39]. Presence of VCP in both ER-associated complex and aggresome as well as its direct association with proteasome indicate that VCP is involved in both retrograde translocation from ER and presentation of client protein to proteasome. We observed the association of VCP with immune complexes pulled down with anti-CFTR, Hsp40, Hsp70, Hsp90, gp78, ataxin-3 (aggresome marker) and HDAC6 antibodies indicating interacting partnerships between these proteins. These results indicated the functional relationship of VCP with both ERAD (Hsp40-Hsp70 complex) and aggresome formation (Ataxin3-HDAC6 complex) pathways
Fig. 2 Summary of misfolded protein disorders. Misfolded protein disorders can be divided into two categories based on (1) loss of misfolded protein by ubiquitin proteasome system (UPS) or endoplasmic reticulum-associated degradation (ERAD) or (2) aggregation of misfolded protein in cytosol (aggresomes) or ER (Russell bodies). Misfolded protein associated with the disease are shown in bracket. above can be translated into a therapeutic intervention. VCP function in protein aggregation disorders that fall under category two needs to be carefully examined, if VCP is responsible for both aggresome formation and promoting degradation of these aggregates as recently proposed by Kobayashi et al. [42]. Inhibiting its interaction with aberrant protein will be effective in inhibiting aggresome formation and will be sufficient to rescue the disease pathology. In disorders where VCP is not required for aggresome formation and is exclusively involved in degradation of these aggregates, methods to enhance AAA ATPase activity or unfoldase function of VCP can be developed as a therapeutic approach to help with the clearance of these aggregates.
Role of VCP in ER and post-ER compartments
Although the mechanism of substrate delivery to the ER membraneassociated retrograde-translocation Derlin1-VCP protein complex is still unclear, there is recent evidence that N-linked glycans play a role in the selective targeting of misfolded glycoproteins to ERAD through interaction with the lectin EDEM (ER degradation-enhancing ␣-mannosidase-like protein; Htm1/Mnl1p in yeast) [43] and VCP regulates this process. The proposed mechanism elucidates that the selection of misfolded glycoproteins is based on the length of time glycoprotein spends in the ER. In the case of prolonged acquisition of a folded conformation, the glycoprotein GlcNAc2-Man9-(Glc1) oligosaccharide becomes a substrate of ER mannosidase I that specifically removes the terminal mannose from the middle branch (branch B), transforming it into GlcNAc2-Man8-Glc1 (also called Man8B-isomer), which functions as the predicted proximal signal for VCP-mediated translocon delivery and ERAD [44]. Accordingly, EDEM and VCP have been shown to accelerate the degradation of misfolded CFTR in yeast. Complementation of the HTM1 (EDEM) or Cdc48 (VCP) deficiency in yeast cells by the mammalian orthologue EDEM or VCP underlines the necessity of these proteins in CFTR degradation and highlights the similarity of quality control and ERAD in yeast and mammals [45]. A novel function of VCP in the control of N-glycosylation of proteins in the ER was recently demonstrated [46]. Mass spectrometric analysis of cellular N-linked glycans revealed that depletion of VCP decreases the level of high-mannose glycoproteins, increases the levels of truncated low-mannose glycoproteins and induces changes in the abundance of complex glycans assembled in post-ER compartments. Since proteasome inhibition was unable to mimic those changes, they cannot be regarded as a simple consequence of inhibited ERAD but represent a complex effect of VCP on the function of the ER. The further examination of the role of VCP in ER protein-glycosylation is required to elucidate the exact function of VCP in selection of misfolded protein for ERAD, aggregation of misfolded proteins in ER (Russell bodies) and trafficking of membrane proteins. In addition, mammalian VCP and its yeast counterpart Cdc48p are also known to participate in the formation of organelles, including the ER, Golgi apparatus and nuclear envelope
Molecular genetics of VCP
Watts et al. [52] identified missense mutations in VCP as the cause of inclusion body myopathy with Paget disease of bone and frontotemporal dementia (OMIM, IBMPFD; 167320). Ten of 13 families
Disease
Chemical chaperone 
VCP structure and biochemical function
Mechanistically, misfolded protein substrates could associate with the N-terminal end of some VCP protomers through their exposed hydrophobic surfaces, whereas adaptors could still occupy other protomers. Although this may still hold, the recent study [55] surprisingly demonstrates the involvement of the D2 ring in substrate binding and propose an in-house mechanism for substrate processing. DeLaBarre and colleagues [55] 
